TherapeuticsMD (TXMD) Gets a Buy Rating from Oppenheimer


Oppenheimer analyst Jay Olson reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) yesterday and set a price target of $14. The company’s shares closed yesterday at $5.16.

Olson wrote:

“TXMD won early FDA approval of Annovera, bolstering an already leading portfolio of differentiated women’s health products. Annovera is a one-year vaginal hormonal system for contraception which TXMD has exclusive US rights to commercialize. This innovative product combines a novel progestin, Nesterone, with estrogen to prevent ovulation for an entire year, thus providing women with long-term yet reversible control over their fertility. This form of contraception represents a significant opportunity as demonstrated by the commercial success of NuvaRing with US sales of $576M in 2017. We update our model to include our forecast of $300M in peak 2024 sales of Annovera assuming 5 years of exclusivity which increases our PT to $14 (vs. $12 prior). We reiterate our Outperform rating.”

According to TipRanks.com, Olson has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.9% and a 38.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on TherapeuticsMD is a Strong Buy with an average price target of $17.50, implying a 239.1% upside from current levels. In a report issued on July 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $26 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.66 and a one-year low of $4.34. Currently, TherapeuticsMD has an average volume of 3.18M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.

Read More on TXMD:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts